CA2958881A1 - Soluble epoxide hydrolase inhibitors and uses thereof - Google Patents

Soluble epoxide hydrolase inhibitors and uses thereof Download PDF

Info

Publication number
CA2958881A1
CA2958881A1 CA2958881A CA2958881A CA2958881A1 CA 2958881 A1 CA2958881 A1 CA 2958881A1 CA 2958881 A CA2958881 A CA 2958881A CA 2958881 A CA2958881 A CA 2958881A CA 2958881 A1 CA2958881 A1 CA 2958881A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
subject
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2958881A
Other languages
English (en)
French (fr)
Inventor
Ying Zhang
Anthony D. Keefe
Christoph Dumelin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
X Chem Inc
Original Assignee
X Chem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Chem Inc filed Critical X Chem Inc
Publication of CA2958881A1 publication Critical patent/CA2958881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2958881A 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof Abandoned CA2958881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462043275P 2014-08-28 2014-08-28
US62/043,275 2014-08-28
PCT/US2015/046878 WO2016033150A1 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CA2958881A1 true CA2958881A1 (en) 2016-03-03

Family

ID=55400481

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2958881A Abandoned CA2958881A1 (en) 2014-08-28 2015-08-26 Soluble epoxide hydrolase inhibitors and uses thereof

Country Status (8)

Country Link
US (2) US10081616B2 (https=)
EP (1) EP3186228A4 (https=)
JP (1) JP2017525777A (https=)
CN (2) CN111454246A (https=)
AU (2) AU2015306643B2 (https=)
CA (1) CA2958881A1 (https=)
MA (1) MA40538A (https=)
WO (1) WO2016033150A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033150A1 (en) * 2014-08-28 2016-03-03 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof
WO2018178253A1 (en) * 2017-03-30 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for use in the treatment of cardiovascular calcification
WO2021127517A1 (en) * 2019-12-18 2021-06-24 Intra-Cellular Therapies, Inc. Novel uses
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245950A1 (de) 1981-12-24 1983-07-07 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur herstellung substituierter pyridine
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
WO2007098352A2 (en) * 2006-02-16 2007-08-30 Boehringer Ingelheim International Gmbh Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
CA2643859A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
EP2054383A2 (en) * 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
EP2129660A2 (en) * 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2002834A1 (de) * 2007-06-13 2008-12-17 Bayer Schering Pharma Aktiengesellschaft Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors
WO2009151800A1 (en) * 2008-05-07 2009-12-17 Merck & Co., Inc. Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
TW201010997A (en) * 2008-06-18 2010-03-16 Pfizer Ltd Nicotinamide derivatives
CA2725481A1 (en) * 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
US20100113512A1 (en) * 2008-10-30 2010-05-06 Diane Michele Ignar Method of treatment using novel antagonists or inverse agonists at opioid receptors
WO2010080183A1 (en) * 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
WO2011091410A1 (en) * 2010-01-25 2011-07-28 Glaxos Smithkline Llc Trpv4 antagonists
US20130102601A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease
US20130102600A1 (en) * 2011-10-21 2013-04-25 F. Hoffmann-La Roche Ltd Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
US8809552B2 (en) * 2011-11-01 2014-08-19 Hoffmann-La Roche Inc. Azetidine compounds, compositions and methods of use
WO2013112751A1 (en) 2012-01-25 2013-08-01 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
HK1212671A1 (zh) * 2012-11-16 2016-06-17 Merck Patent Gmbh 3-氨基环戊烷甲酰胺衍生物
CN104016914B (zh) 2014-05-27 2016-03-30 苏州科技学院 一种酰胺化合物的制备方法
WO2016033150A1 (en) * 2014-08-28 2016-03-03 X-Chem, Inc. Soluble epoxide hydrolase inhibitors and uses thereof

Also Published As

Publication number Publication date
MA40538A (fr) 2021-04-07
AU2020207828A1 (en) 2020-08-13
EP3186228A4 (en) 2018-04-18
US20180362499A1 (en) 2018-12-20
US10081616B2 (en) 2018-09-25
JP2017525777A (ja) 2017-09-07
AU2015306643A1 (en) 2017-03-16
CN111454246A (zh) 2020-07-28
EP3186228A1 (en) 2017-07-05
CN107074771B (zh) 2020-03-20
AU2015306643B2 (en) 2020-05-07
CN107074771A (zh) 2017-08-18
US20170240526A1 (en) 2017-08-24
WO2016033150A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
US10562870B2 (en) Prodrugs of riluzole and their method of use
AU2020207828A1 (en) Soluble epoxide hydrolase inhibitors and uses thereof
US10487087B2 (en) Positive allosteric modulators of the GLP-1 receptor
US11325896B2 (en) Antagonists of the muscarinic acetylcholine receptor M4
EP3677584A1 (en) Compound having bruton's tyrosine kinase (btk)-inhibition and degradation activity
US20240294489A1 (en) Low molecular weight protein degraders and their applications
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
EP3746421B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US11225484B2 (en) Substituted octahydropyrrolo[3,4-b]pyrroles as antagonists of the muscarinic acetylcholine receptor M4
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
US12084451B2 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
WO2020198275A1 (en) Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment
KR102905373B1 (ko) 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물
JP2020152641A (ja) リジン特異的脱メチル化酵素１阻害活性を有する新規化合物、その製造方法及びその用途
WO2013192610A2 (en) Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
CA3021558A1 (en) Covalent btk inhibitors and uses thereof
WO2019079609A1 (en) SEH / PDE4 DOUBLE INHIBITORS AVAILABLE ORAL
US20150361081A1 (en) Negative allosteric modulators of metabotropic glutamate receptor 3
CN118251379B (zh) 铁死亡抑制剂及其用途
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
KR20240066904A (ko) 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20150051016A (ko) 구아니딘 화합물 및 이의 용도

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123